Pfizer, Inc. News

Do you have an interest in the products developed by Pfizer, Inc., or are you interested in the performance of the company? If you are you should register for the free Pfizer, Inc. news email from Wiser. Pfizer, Inc. is an American-based pharmaceutical company that researches, develops and manufactures medicines and vaccines. The products developed by the company are used all over the world. They include leading brands like Lipitor, Zithromax and Viagra. The company was founded in 1849 and today is one of the largest pharmaceutical companies in the world. Its current chairman and CEO is Ian Reed. Most analysts expect Pfizer, Inc. to expand through acquisitions over the coming years. The Wiser daily Pfizer, Inc. news email covers this news as well as analysis on the performance of the company, and details about its products. These articles come from the best sources around the web and are delivered in a comprehensive but simple to use format. Sign up today.

Recent Pfizer, Inc. News Coverage
 
Your Weekly Recommendations Tuesday, April 25, 2017
 
Recommended for you
FDA Approves New Drug That Could Take a Slice Out of Johnson & Johnson’s Best Seller
Fortune Magazine • Sy Mukherjee
Earnings Preview: Lilly, Lockheed Martin, And Caterpillar Report Tomorrow
Seeking Alpha • J.J. Kinahan
Merck: Strong Research And Bolt-On Acquisitions
Seeking Alpha • Dividend Sleuth
Lilly reports positive interim data on breast cancer combo drug
Reuters
Brainstorm Health Daily: April 24, 2017
Fortune Magazine • Clifton Leaf, Sy Mukherjee
Buy This Buffett Portfolio At A 16.5% Discount And Get A 4.4% Yield
Seeking Alpha • Left Banker
3% Dividend Yield Is Great, But What Else Do You Need?
Seeking Alpha • Colorado Wealth Management Fund
Hiding Data And Other Criticisms Of Big Pharma
Forbes • Contributor, John Lamattina
Neglected no more: ending trachoma, an infectious eye disease rooted in poverty
The Guardian • Anthony Solomon, Victor Florea
NASH: The next untapped pharma market gives investors many options
Reuters
 
Recommended for You
Johnson & Johnson, Merck & Co., Inc.
FDA Approves New Drug That Could Take a Slice Out of Johnson & Johnson’s Best Seller
Fortune MagazineSy Mukherjee
Pharma giant Johnson & Johnson's Remicade brought in nearly $7 billion in sales last year. But Samsung Bioepis and partner Merck are hoping to claw away some of that market share with a new rival therapy—one that could come at a significant...
Share
American Express Co, Defense Contracting
Earnings Preview: Lilly, Lockheed Martin, And Caterpillar Report Tomorrow
Seeking AlphaJ.J. Kinahan
Summary Two industrial bellwethers, General Electric (GE) and Honeywell (HON), just beat Wall Street analyst expectations on Friday. Credit card companies American Express (AXP) and Visa (V) also reported strong results. Get a look into pharma, defense, and construction when CAT, LMT...
Share
Health Finance, Merck & Co., Inc.
Merck: Strong Research And Bolt-On Acquisitions
Seeking AlphaDividend Sleuth
Summary Why I bought Merck. Growth through research and bolt-on acquisitions, not blockbusters. Some Vital Statistics: Price/Operating Earnings. Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE) and Merck & Co. (NYSE:MRK) comprise 10% of my portfolio. I briefly highlighted JNJ in last month's portfolio...
Share
Cancer, Health Care Industry
Lilly reports positive interim data on breast cancer combo drug
Reuters
(Reuters) - Eli Lilly and Co said the combination of its experimental breast cancer drug and a commonly used treatment met the main goal of a late-stage study in an interim analysis, setting the stage for a regulatory submission later this year.
Share
Pfizer, Inc., Reddit
Brainstorm Health Daily: April 24, 2017
Fortune MagazineClifton Leaf, Sy Mukherjee
They gathered at a biomedical research park in Barcelona, outside the Queensland Parliament House in Brisbane, and in a 70-person huddle in Blantyre, Malawi, chanting “Taima nji” (“We are standing strong”). They stormed the capitals of London, Paris, Tokyo, and Mexico City;...
Share
Finance, Investment Industry
Buy This Buffett Portfolio At A 16.5% Discount And Get A 4.4% Yield
Seeking AlphaLeft Banker
Summary This fund holds a portfolio built on Warren Buffett's investment choices. It has beaten both the broad market and the large-cap value segment by a solid margin. The fund pays an attractive 4.4% distribution in monthly increments. It is priced at...
Share
Finance, Investment Industry
3% Dividend Yield Is Great, But What Else Do You Need?
Seeking AlphaColorado Wealth Management Fund
Summary VYM is a great ETF, though most of the market is dreadfully expensive. The companies with VYM represent several of the top tier choices for building a dividend growth portfolio. The fund is designed for dividend growth investors. When the market...
Share
Health Care Industry, Pfizer, Inc.
Hiding Data And Other Criticisms Of Big Pharma
ForbesContributor, John Lamattina
However, the pendulum has swung dramatically in recent years, particularly with respect to reporting negative clinical trial results.
Share
Epidemiology, Infectious Disease
Neglected no more: ending trachoma, an infectious eye disease rooted in poverty
The GuardianAnthony Solomon, Victor Florea
In proportion to their collective contribution to human suffering, neglected tropical diseases (NTDs) have received insufficient attention. Today, thanks to incremental progress in the science of public health, growing programmatic experience and commitment from endemic country governments, donors and other partners, we...
Share
Cancer, Gilead Sciences
NASH: The next untapped pharma market gives investors many options
Reuters
(Reuters) - Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.
Share